Cannabis compounds can prevent COVID-19 infection, study finds

According to a new study by researchers affiliated with Oregon State University, compounds found in cannabis can prevent the virus that causes COVID-19 from infecting human cells.

An abstract of the study was published Monday in the Journal of Natural Products.

The researchers found that two compounds, cannabigerolic acid (CBGA) and cannabidiolic acid (CBDA), could prevent COVID-19 infections by gumming up the spike proteins of the coronavirus SARS-CoV-2, which the virus uses to enter cells.

“Any part of the infection and replication cycle is a potential target for antiviral intervention, and the connection of the spike protein’s receptor binding domain to the human cell surface receptor ACE2 is a critical step in that cycle,” lead researcher Richard van Breemen said, according to KVAL-TV in Oregon. “That means cell entry inhibitors, like the acids from hemp, could be used to prevent SARS-CoV-2 infection and also to shorten infections by preventing virus particles from infecting human cells. They bind to the spike proteins so those proteins can’t bind to the ACE2 enzyme, which is abundant on the outer membrane of endothelial cells in the lungs and other organs.”

The researchers tested the compounds against the “alpha” and “beta” variants of the virus in human cells in a lab, and van Breeman said they “hope that trend will extend to other existing and future variants” of the virus, according to KVAL-TV, adding that “the combination of vaccination and CBDA/CBGA treatment should make for a much more challenging environment for SARS-CoV-2.”

Though the study did not use human test subjects, the researchers noted that the compounds have “a long history of safe human use.” The compounds are found in the raw form of hemp, known scientifically as Cannabis sativa.

“These cannabinoid acids are abundant in hemp and in many hemp extracts,” van Breemen said, according to KVAL-TV. “They are not controlled substances like THC, the psychoactive ingredient in marijuana, and have a good safety profile in humans.” 

Of course, much more research is needed, so don’t think you can just load up your bong for a COVID-19 cure.

Increasing Use of Cannabis Derivatives As a Therapy to Treat or Alleviate Symptoms of Chronic Illnesses to Drive Revenue Growth of Medical Marijuana Market: Reports and Data

Extensive R&D activities to expand therapeutic use of cannabis, implementation of favorable government regulations, and advancements in medical cannabis-based medicines as treatment for substance abuse are some key factors expected to drive market growth

NEW YORK, Jan. 12, 2022 /PRNewswire/ — Reports and Data has published its latest report titled “Medical Marijuana Market, By Product Type (Oil, Buds, and Tinctures), By Route of Administration (Inhalation, Oral, Intravenous, and Topical), By Application, By Distribution Channel, and By Region Forecast to 2028.”

According to the latest report by Reports and Data, the global medical marijuana market size was USD 10.20 billion in 2020 and is expected to reach USD 24.52 billion in 2028 and register a revenue CAGR of 11.5% during the forecast period, 2021-2028.

Drivers, Restraints, and Opportunities

Medical cannabis is extensively being used in palliative care to alleviate a multitude physical and psychological symptoms. Cannabis is classified as a schedule I controlled substance in the United States, however, over the recent past, increasing number of states have legalized cannabis for medical applications. Medical marijuana is effective in relieving certain types of chronic pain such as pain associated with cancer, HIV, neuropathic, and multiple sclerosis. Wide availability of marijuana and increasing acceptance of it as a medical modality is expected to further promote its use for self-medication in cases such as minimizing the effects of posttraumatic stress and this is expected to significantly contribute to revenue growth of the market over the forecast period.  

Medical marijuana is often prescribed by physicians and can be taken by various methods such as capsules, oral or dermal sprays, and cannabis edibles, among others. In the recent years, extensive research has been carried out to assess therapeutic effects of medical cannabis and it has been found that it reduces nausea during chemotherapy, improves appetite in HIV/AIDS, improves sleep, and has also been recommended for anorexia, arthritis, and migraine when conventional treatments do not work. Medical cannabis and cannabis-based medicines are also being used to develop drug addiction disorder treatments or as substitutes for alcohol and other drugs such as opiates. Certain research studies suggest cannabinoids that activate the CB2 receptor can provide safe treatment for drug addiction and withdrawal symptoms through its anti-inflammatory effects and pain relief. This is further boosting use of medical marijuana across the globe and is another factor expected to contribute to revenue growth of the market over the forecast period.

Medical marijuana products can be obtained from pharmacies and programs and follow robust regulatory requirements concerned with manufacturing, marketing, and distribution. In addition, increasing legalization of medical marijuana in various countries across the globe is another factor expected to support market growth. However, certain side effects associated with administration of medical marijuana such as fatigue and dizziness, stringent regulations regarding manufacturing of marijuana, and controversies surrounding use of cannabis-based products are some factors expected to restrain market growth to a certain extent over the forecast period.

COVID-19 Impact Analysis

  • Social distancing and restrictions severely disrupted businesses and operations
  • Lockdowns caused disruptions in transportation and logistics
  • Impacted manufacturing activities and mining operations globally
  • Took a toll on economy of various countries
  • Caused sudden and drastic downturn in economic activity
  • Disrupted agriculture, fisheries, dairy, and other sectors
  • Caused loss of employment and financial crisis
  • Supply impacts were further compounded owing to reduced disposable income
  • Emergence of variants continue to cause concerns and impact normal routines

Oil Segment Revenue to Support Market Growth:

The oil segment revenue is expected to expand at a rapid CAGR over the forecast period owing to increasing demand for hemp oil for clinical purposes in healthcare sector and increasing prescription of oil or edible forms of marijuana.

Topical Segment to Lead in Terms of Revenue Growth:

Topical segment is expected to dominate other route of administration insights in terms of revenue growth over the forecast period attributable to increasing demand for marijuana as topical lotions, ointments, creams, and gels to treat skin inflammation, burns, infections, and abrasions, among others.

North America to Account for Largest Revenue Share:

North America is expected to account for largest revenue share over the forecast period attributable to increasing adoption of marijuana-based products to treat various chronic conditions, rising government initiatives to promote cannabis-derivatives such as oils and resins, and legalization of medical marijuana in countries in the region.

Europe to Register Robust Revenue CAGR:

Europe is expected to register robust revenue CAGR over the forecast period attributable to rapid adoption of and legalization of medical marijuana, presence of larger consumer base, increasing incidence of chronic diseases and focus on palliative care, and larger markets for marijuana in European countries such as Germany.

Major Companies in the Market Include:

  • Canopy Growth Corporation
  • Aphria, Inc.
  • Aurora Cannabis
  • Maricann Group, Inc.
  • Tilray
  • Cronos Group
  • Organigram Holdings
  • Inc., Vivo Cannabis
  • Tikun Olam
  • Insys Therapeutics, Inc.

Market Segmentation:

For this study, Reports and Data has segmented the global medical marijuana market based on product type, route of administration, application, distribution channel, and region:

Product Type Outlook (Revenue, USD Billion; 2018–2028)

  • Oil
  • Buds
  • Tinctures

Rout of Administration Outlook (Revenue, USD Billion; 2018–2028)

  • Inhalation
  • Oral
  • Intravenous
  • Topical

Application Outlook (Revenue, USD Billion; 2018–2028)

  • Chronic Pain
  • Mental Disorders
  • Anorexia
  • Seizures
  • Muscle Spasm
  • Cancer
  • Others

Distribution Channel Outlook (Revenue, USD Billion; 2018–2028)

  • Dispensaries
  • Online

Regional Outlook (Revenue, USD Billion; 2018–2028)

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Sweden
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • Saudi Arabia
    • U.A.E.
    • South Africa
    • Israel
    • Rest of MEA

Some points on how the report benefits stakeholders:

  • The reports include historical (2018–2020) and forecast (2021–2028) data points, revenues, and CAGR in table, figure, and chart formats, with detailed and qualitative, supporting written information for each.
  • Revenue break-up is provided for each segment in these formats for global, regional, and for each country in the respective region for each year between 2018 and 2028.
  • The report contains insights regarding growth drivers, restraints, opportunities, trends, company profiles, strategic developments, expansion details, product launches, and various other aspects related to the market.
  • The report contains data and information on customers, competitors, vendors/distributors, and other players and in the global marketplace.
  • Market research analysis is vital for all crucial business strategies and can aid in numerous ways and to provide a clearer understanding about strategies being deployed by competitors, product launches, competitive analysis, technological advancements and various other factors that enhance sales of a firm or perhaps provide insights to focus on merger and acquisition as a strategy or enter into strategic agreements or joint ventures etc.
  • The report contains company profiles of the top companies operating in the market along with their respective revenue and operating segments, geographical reach, market footprint, headquarters, growth rates, recent developments, product /services, expansion strategies, investments in expansion, and more.

Explore Trending Research Reports by Reports and Data:

Transfer membrane market size was USD 181 million in 2020 and is expected to register a CAGR of 1.7% during the forecast period. Steady global market revenue growth is attributed to various factors such as significant increase in prevalence of new and target diseases worldwide, surging research & development activities in pharmaceutical and biotechnological industries globally, and increased public and private investments in the life sciences industry.

Rabies diagnostics market size was USD 1.69 billion in 2020 and is expected to register a CAGR of 4.4% during the forecast period. Growing trend of pet ownership, rising prevalence of infectious and animal-borne diseases such as rabies, and other Neglected Tropical Diseases (NTDs) in densely populated and low-income regions are among the pivotal factors propelling the global market growth.

Protein binding assay market size was USD 374.06 million in 2020 and is expected to register a CAGR of 10.8% during the forecast period. Increasing focus on new drug discovery and development processes and rapid developments in pharmaceutical and biotechnological industries are primary factors fueling global protein binding assay market revenue growth.

Point-of-care (PoCT) glucose testing market size was USD 6.39 billion in 2020 and is expected to register a CAGR of 3.12% during the forecast period. Rising prevalence of diabetes, increasing patients’ preference for testing and treatment in home care settings, growing need for bedside monitoring, and increasing demand for point-of-care testing are key factors expected to drive market revenue growth over the forecast period.

Organs-on-chips market size was USD 24.4 million in 2020 and is expected to register a CAGR of 36.5% during the forecast period. Growing requirement for alternatives for animal testing and rising need for early detection of drug toxicity are primary factors driving the revenue growth of the global organs-on-chips market.

About Reports and Data     

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Polls Funded By Marijuana Prohibitionist Group Show Big Support For Legalization Policies It Lobbies Against

A set of new national and state surveys funded by the prohibitionist group Smart Approaches to Marijuana (SAM) found that a large majority of Americans think cannabis should be legal for either medical or recreational purposes.

That’s not how SAM is presenting the findings of the Emerson College polls, though. The group is attempting to argue that when people are presented with several marijuana reform options that only a minority support full adult-use legalization.

The survey found that, of the four separate options included, support for recreational legalization was highest, with 38 percent of U.S. voters backing it. That was followed by support for medical cannabis legalization (30 percent), decriminalization (19 percent) and prohibition (14 percent).

In other words, about 68 percent of Americans favor some form of legal, regulated marijuana—the types of systems that SAM regularly works to oppose when proposals go before lawmakers during legislative sessions or voters at the ballot box.

But the group is really leaning into the fact that recreational cannabis on its own only got a plurality of support. In one chart, they contrasted adult-use responses with all three other options to make it look like people prefer “Other Non-Legalization Marijuana Policies.”

They included responses for prohibition, decriminalization and medical marijuana in that category, despite the fact that medical cannabis is a form of legalization that’s in effect in most states, and it was among the most popular options.

“Big Pot, which is rapidly being taken over by the giants of Big Tobacco, Big Alcohol, and even Big Pharma, wants lawmakers to believe it enjoys widespread support among voters,” SAM President Kevin Sabet argued in a press release. “It pushes this false narrative with the public and uses decision-makers to expand its addiction-for-profit business model.”

The “false narrative” is also supported by numerous other polls, including from reputable sources like Gallup and Pew Research Center that ostensibly are not bought out by the tobacco and alcohol lobby. Most Americans have been saying in no uncertain terms for years now that cannabis should be legal.

This latest survey involved interviews with 1,000 Americans from January 7-9. SAM also commissioned surveys to specifically look at cannabis attitudes in Maryland and New Hampshire, where lawmakers and advocates are actively working to advance legalization this year.

For Maryland, SAM again argued that its data shows majority opposition to recreational legalization. But again, what the survey found was that the most popular of the four options was adult-use legalization (45 percent), followed by medical cannabis legalization (27 percent), decriminalization (13 percent) and prohibition (16 percent).

The spin on the results could be put to the test if the Maryland legislature approves a recent bill from Del. Luke Clippinger (D) to put legalization on the state’s 2022 ballot.

“Maryland lawmakers have routinely batted down Big Pot’s attempts to expand its addiction-for-profit model and this poll finds Maryland voters overwhelmingly support their continued resistance to implement a taxed commercial market,” Sabet said.

For its New Hampshire survey, there’s the same theme. Support for recreational was highest (47 percent), then medical (21 percent), then prohibition (18 percent) and then decriminalization (13 percent).

The SAM statement on the New Hampshire poll is a copy-and-paste of the Maryland statement, just swapping out the state names.

“New Hampshire lawmakers have routinely batted down Big Pot’s attempts to expand its addiction-for-profit model and this poll finds New Hampshire voters overwhelmingly support their continued resistance to implement a taxed commercial market,” Sabet said.

In that state, the GOP-controlled House approved a bill last week to legalize marijuana possession and personal cultivation for adults. It’s one of several legalization proposals that have been filed in the legislature for 2022, including some that would put the issue of ending cannabis prohibition to voters on the November ballot.

What is CBD?

Cannabidiol (CBD) is a chemical in the Cannabis sativa plant, also known as cannabis or hemp.

Over 80 chemicals, known as cannabinoids, have been found in the Cannabis sativa plant. Delta-9-tetrahydrocannabinol (THC) is the most famous ingredient in cannabis. But CBD is obtained from hemp, a form of the Cannabis sativa plant that only contains small amounts of THC. CBD seems to have effects on some chemicals in the brain, but these are different than the effects of THC.